SOPHiA GENETICS (NASDAQ:SOPH) Insider Well Daan Van Sells 6,168 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Well Van sold 6,168 shares of the stock in a transaction on Friday, September 11th. The shares were sold at an average price of $7.63, for a total value of $47,061.84. Following the transaction, the insider directly owned 338,884 shares of the company’s stock, valued at approximately $2,585,684.92. The trade was a 1.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

SOPHiA GENETICS Stock Down 0.1%

Shares of SOPH stock opened at $7.86 on Tuesday. SOPHiA GENETICS SA has a 1 year low of $3.12 and a 1 year high of $8.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. The business’s fifty day moving average is $7.08 and its 200-day moving average is $5.71. The stock has a market cap of $659.38 million, a PE ratio of -6.83 and a beta of 0.98.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The firm had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. Equities analysts expect that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. First Dallas Securities Inc. purchased a new position in SOPHiA GENETICS during the 1st quarter valued at about $50,000. Royal Bank of Canada grew its position in SOPHiA GENETICS by 3,130.2% in the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after acquiring an additional 18,781 shares in the last quarter. AXQ Capital LP acquired a new position in SOPHiA GENETICS during the second quarter worth $119,000. Silverberg Bernstein Capital Management LLC increased its holdings in shares of SOPHiA GENETICS by 8.7% during the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock valued at $257,000 after acquiring an additional 4,155 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. acquired a new position in SOPHiA GENETICS during the second quarter valued at approximately $567,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Wall Street Analyst Weigh In

SOPH has been the subject of a number of research analyst reports. HC Wainwright upped their price target on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. BTIG Research boosted their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Finally, Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $10.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS Ltd. is a healthcare technology company that develops data-driven medicine solutions for healthcare institutions, pharmaceutical companies and research organizations. The company’s platform is designed to help users analyze complex genomic and multimodal data and apply insights to clinical research and patient care.

Its core offering, the SOPHiA DDM platform, combines cloud-based software, artificial intelligence and machine-learning tools to support the interpretation of genomic data.